Dexamethasone & Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations
A Comparative Study Between Dexamethasone and Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Wound infiltration with local anaesthetics is a simple, effective and inexpensive means of providing good analgesia for a variety of surgical procedures without any major side-effects.
Patients and Methods Type of Study:Randomized, controlled, double-blind study.
Study Setting: Ain Shams university hospitals.
Study Period: 3months after approval of the ethical committee.
Study Population:
Inclusion Criteria:
Children of both sexes aged 1-8 years, ASA I-II, undergoing moderate to major abdominal operations.
Exclusion Criteria:
History of diabetes, cardiac or neurological disease Hypersensitivity to any of the drugs used in the study Risk of wound complications ( as infected wound, history of wound dehiscence, hypo-albuminaemia) Multiple incision sites Operations scheduled as day-case
Sample size: using PASS program version 15, setting alpha error at 5%and power at 80%. Based on previous studies the needed sample is 50 cases per group (total 150 patients).
Sampling Method: simple random sampling Children will be randomized into three groups 50 patients each.
- Group I: Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
- Group II: In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
- Group III: In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
Study Tools and Study Procedures:
In all groups, drugs will be prepared by the attending anesthesiologist and injected by the surgeon (both will be blinded to the procedure) Anesthetic technique In all children, anesthesia will be induced by sevoflurane or propofol 2mg/kg IV, fentanyl 2ug/kg, atracurium 0.5 mg/kg followed by endotracheal intubation and mechanical ventilation with pressure controlled mode. Anesthesia will be maintained with sevoflurane in oxygen. All children will be monitored using ECG, non invasive blood pressure cuff, pulse oximeter and temperature probe. Ringer acetate will be used as the replacement fluid. At conclusion of surgery, the trachea will be extubated after reversal of the muscle relaxant with neostigmine 0.05 mg/kg + atropine 0.02 mg/kg and the child transferred to the postanesthesia care unit.
Comparisons will be done between both groups as regards: time needed for first analgesic dose (primary outcome), The FLACC pain scale will be assesed over a 24hour period as follows: (table 1) in PACU, then 2 hourly for 12 hours then 4 hourly.),Total number of administrations of rescue analgesia in the first 24 hours postoperatively, incidence of wound complications over a 7 d period (secondary outcomes)
First analgesic dose:
If the FLACC scale was more than 3 either during intervals of FLACC recording or in between, intravenous paracetamol was provided at a dose of 15mg/kg then fixed around the clock every 6 hours.
Rescue analgesia If pain persisted or recurred rectal diclophenac 1mg/kg or ibuprophen in children in whom oral intake has been allowed.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Al Abbassia
-
Cairo, Al Abbassia, Egypt, 11591
- Ain shams university hospitals
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children of both sexes aged 1-8 years, ASA I-II, undergoing moderate to major abdominal operations.
Exclusion Criteria:
- History of diabetes, cardiac or neurological disease
- Hypersensitivity to any of the drugs used in the study.
- Risk of wound complications ( as infected wound, history of wound dehiscence, hypo--albuminaemia)
- Multiple incision sites
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group 1
Control Group (Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure).
|
Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
|
|
Active Comparator: Group 2
Ketamine Group (In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure.
Bupivacaine and ketamine will be administered using two separate syringes).
|
Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure.
Bupivacaine and ketamine will be administered using two separate syringes.
|
|
Active Comparator: Group 3
Dexamethasone Group (In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure.
Bupivacaine and dexamethsone will be administered using two separate syringes).
|
Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure.
Bupivacaine and dexamethsone will be administered using two separate syringes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Face, Leg, Activity, Cry and Consolability scale (FLACC) pain scale
Time Frame: At Time zero (The time of extubation)
|
-Face: No particular expression or smile (0) Occasional grimace or frown, withdrawn, disinterested (1) Frequent to constant frown, clenched jaw, quivering chin (2) -Legs: Normal position or relaxed (0) Uneasy, restless, tense (1) Kicking, legs drawn up (2) -Activity: Lying quietly, normal position, moves easily (0) Squirming, shifting back and forth, tense (1) Arched, rigid or jerking (2) -Cry: No crying (awake or asleep) (0) Moans or whimpers, occasional complaint (1) Crying steadily, screamsor sobs, frequent complaints (2) -Consolability: Content, relaxed (0) Reassured by occasional touching, hugging or talking to, distractable (1) Difficult to console or comfort (2) The scale range from 0 to 10. The higher the number the worse the pain status. |
At Time zero (The time of extubation)
|
|
The Face, Leg, Activity, Cry and Consolability scale (FLACC) pain scale
Time Frame: At 2 hours postoperatively
|
-Face: No particular expression or smile (0) Occasional grimace or frown, withdrawn, disinterested (1) Frequent to constant frown, clenched jaw, quivering chin (2) -Legs: Normal position or relaxed (0) Uneasy, restless, tense (1) Kicking, legs drawn up (2) -Activity: Lying quietly, normal position, moves easily (0) Squirming, shifting back and forth, tense (1) Arched, rigid or jerking (2) -Cry: No crying (awake or asleep) (0) Moans or whimpers, occasional complaint (1) Crying steadily, screamsor sobs, frequent complaints (2) -Consolability: Content, relaxed (0) Reassured by occasional touching, hugging or talking to, distractable (1) Difficult to console or comfort (2) The scale range from 0 to 10. The higher the number the worse the pain status. |
At 2 hours postoperatively
|
|
The Face, Leg, Activity, Cry and Consolability scale (FLACC) pain scale
Time Frame: At 12 hours postoperatively
|
Face: No particular expression or smile (0) Occasional grimace or frown, withdrawn, disinterested (1) Frequent to constant frown, clenched jaw, quivering chin (2) -Legs: Normal position or relaxed (0) Uneasy, restless, tense (1) Kicking, legs drawn up (2) -Activity: Lying quietly, normal position, moves easily (0) Squirming, shifting back and forth, tense (1) Arched, rigid or jerking (2) -Cry: No crying (awake or asleep) (0) Moans or whimpers, occasional complaint (1) Crying steadily, screamsor sobs, frequent complaints (2) -Consolability: Content, relaxed (0) Reassured by occasional touching, hugging or talking to, distractable (1) Difficult to console or comfort (2) The scale range from 0 to 10. The higher the number the worse the pain status. |
At 12 hours postoperatively
|
|
The Face, Leg, Activity, Cry and Consolability scale (FLACC) pain scale
Time Frame: At 24 hours postoperatively
|
Face: No particular expression or smile (0) Occasional grimace or frown, withdrawn, disinterested (1) Frequent to constant frown, clenched jaw, quivering chin (2) -Legs: Normal position or relaxed (0) Uneasy, restless, tense (1) Kicking, legs drawn up (2) -Activity: Lying quietly, normal position, moves easily (0) Squirming, shifting back and forth, tense (1) Arched, rigid or jerking (2) -Cry: No crying (awake or asleep) (0) Moans or whimpers, occasional complaint (1) Crying steadily, screamsor sobs, frequent complaints (2) -Consolability: Content, relaxed (0) Reassured by occasional touching, hugging or talking to, distractable (1) Difficult to console or comfort (2) The scale range from 0 to 10. The higher the number the worse the pain status. |
At 24 hours postoperatively
|
|
Rescue analgesia
Time Frame: 24 hours
|
Time needed for first rescue analgesia
|
24 hours
|
|
Total dose of rescue analgesia in the first 24 hours postoperatively.
Time Frame: 24 hours
|
Total dose of rescue analgesia in the first 24 hours postoperatively.
If pain persisted or recurred rectal diclophenac 1mg/kg.
total dose measured in milligrams
|
24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of wound complications
Time Frame: 72 hours
|
Incidence of wound infection or dehiscence, descirbed in the form of occured or not occured.
|
72 hours
|
|
Incidence of postoperative nausea and vomiting
Time Frame: 24 hours
|
Incidence of postoperative nausea and vomiting discribed in the form of occured or not occured
|
24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anesthetics, Local
- Ketamine
- Dexamethasone
- Bupivacaine
Other Study ID Numbers
Other Study ID Numbers
- FMASU R 122A/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric ALL
-
NCT03455140CompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AML
-
NCT07527546Not yet recruitingPediatric Anesthesia | Pediatric Postoperative Recovery | Pediatric Enhanced Recovery After Surgery
-
NCT02638428RecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor
-
NCT02904278CompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac Transplantation
-
NCT07493018Not yet recruitingPediatric Oncology | Pediatric Hematology
-
NCT07371026Not yet recruitingPediatric | Pediatric Acute Upper Respiratory Tract Infection | Pediatric Acute Respiratory Failure
-
NCT03939728TerminatedPediatric Lung Ultrasound | Pediatric Chest Radiography | Pediatric Lung Diagnosis
-
NCT04944875CompletedPediatric Cancer | Pediatric Brain Tumor | Pediatric Solid Tumor
-
NCT07617662Not yet recruitingPediatric Dental Anxiety | Pediatric Dental Pain
Clinical Trials on Bupivacaine
-
NCT07418671CompletedErector Spinae Plane Block | Post-operative Pain | Total Hip Arthroplasty (THA)
-
NCT07458282RecruitingLaparoscopic Surgery | Transversus Abdominis Plane Block | Liposomal Bupivacaine
-
NCT07442539RecruitingPain Management | Local Infiltration | Liposome Bupivacaine | Hemorrhoid Surgery
-
NCT07441902RecruitingPain Management | Video-assisted Thoracoscopic Surgery (VATS) | Liposomal Bupivacaine | Rhomboid Intercostal Block
-
NCT07432711RecruitingPain Management | Video-assisted Thoracoscopic Surgery (VATS) | Liposomal Bupivacaine | Local Injection
-
NCT07458295RecruitingLaparoscopic Surgery | Transversus Abdominis Plane Block | Gynecologic Oncology Patient | Liposomal Bupivacaine
-
NCT07458256RecruitingLaparoscopic Surgery | Local Infiltration | Liposomal Bupivacaine
-
NCT07535411Not yet recruiting
-
NCT07512635Not yet recruitingPulmonary Nodule | Liposomal Bupivacaine